Among patients with T2DM, insulin treatment was associated with a higher risk of primary endpoint (P = 0.03), and patients with T2DM duration of > 4 years also showed an increased risk of clinical outcomes (P = 0.03) (Fig. 4). Here, INS is linked to type 2 diabetes mellitus.